SCHEMBL3534282

SCHEMBL3534282

C[C@H]1CN(c2ccc3[nH]c(-c4n[nH]c5cc(F)ccc45)nc3c2)CCN1C

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 7/20 0.54
FLT1 P17948 5/20 0.54
KDR P35968 3/20 0.54
CDK2 P24941 3/20 0.44
ADRA2A P08913 3/20 0.44
ADRA2C P18825 3/20 0.44
ADRA2B P18089 2/20 0.44
CDK4 P11802 1/20 0.44
CCNA2 P20248 1/20 0.44
CCND1 P24385 1/20 0.44
CCND3 P30281 1/20 0.44
PRKCZ Q05513 2/20 0.43
CHEK1 O14757 1/20 0.41
HTR2A P28223 1/20 0.41
PDGFRB P09619 2/20 0.41
ABL1 P00519 2/20 0.40
PDPK1 O15530 2/20 0.40
FLT3 P36888 1/20 0.39
LRRK2 Q5S007 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3534274 0.93 FGFR1 (0.64) FGFR1FLT1KDRCDK2ADRA2A
SCHEMBL3540418 0.93 FGFR1 (0.64) FGFR1FLT1KDRCDK2ADRA2A
SCHEMBL3540421 0.93 FGFR1 (0.64) FGFR1FLT1KDRCDK2ADRA2A
SCHEMBL3542742 0.87 FGFR1 (0.57) FGFR1FLT1KDRADRA2AADRA2C
SCHEMBL3542736 0.87 FGFR1 (0.57) FGFR1FLT1KDRADRA2AADRA2C
SCHEMBL3545248 0.87 FGFR1 (0.57) FGFR1FLT1KDRADRA2AADRA2C
SCHEMBL3535282 0.86 FGFR1 (0.50) FGFR1FLT1KDRCDK2CDK4
SCHEMBL3538226 0.81 FGFR1 (0.57) FGFR1FLT1KDRCDK2ADRA2A
SCHEMBL3542278 0.81 FGFR1 (0.57) FGFR1FLT1KDRCDK2ADRA2A
SCHEMBL3538223 0.81 FGFR1 (0.57) FGFR1FLT1KDRCDK2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885KDR 2852/4885
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 FGFR1 2175/4885FLT1 3562/4885KDR 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.